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Abstract
Background: Hypoglycaemia due to hyperinsulinism (HI) is the commonest cause of severe, recurrent
hypoglycaemia in childhood. Cohort outcomes of HI remain to be described and whilst previous follow up studies
have focused on neurodevelopmental outcomes, there is no information available on feeding and auxology.
Aim: We aimed to describe HI outcomes for auxology, medications, feeding and neurodevelopmental in a cohort
up to age 5 years.
Method: We reviewed medical records for all patients with confirmed HI over a three-year period in a single centre
to derive a longitudinal dataset.
Results: Seventy patients were recruited to the study. Mean weight at birth was − 1.0 standard deviation scores
(SDS) for age and sex, while mean height at 3 months was − 1.5 SDS. Both weight and height trended to the
population median over the follow up period. Feeding difficulties were noted in 17% of patients at 3 months and
this reduced to 3% by 5 years. At age 5 years, 11 patients (15%) had neurodevelopmental delay and of these only
one was severe. Resolution of disease was predicted by lower maximum early diazoxide dose (p = 0.007) and being
born SGA (p = 0.009).
Conclusion: In a three-year cohort of HI patients followed up for 5 years, in spite of feeding difficulties and
carbohydrate loading in early life, auxology parameters are normal in follow up. A lower than expected rate of
neurodevelopmental delay could be attributed to prompt early treatment.
Keywords: Congenital Hyperinsulinism, Natural history, Height, Weight, Diazoxide, Outcomes, Hypoglycaemia,
Neurodevelopment
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Background
Hyperinsulinism (HI) is a rare group of disorders charac-
terised by dysregulated insulin secretion leading to un-
predictable hypoglycaemia. The estimated incidence
ranges from 1:2500 to 1:50,000 with higher rates among
consanguineous populations [1, 2]. Although rare, HI is
the commonest cause of severe, recurrent hypoglycaemia
in infancy and childhood [1]. HI is a heterogeneous con-
dition with just under half of patients found to have gen-
etic mutations [3]. In many patients, gene mutations are
often not identified, even though genetic aetiology may
still be possible. HI can be classified as diffuse or focal,
depending on histopathological characteristics following
18F-DOPA positron emission tomography. The distinc-
tion of focal HI from diffuse HI is clinically relevant as
treatment in the former is predominantly surgical lesio-
nectomy with the possibility of cure. In some patients
with HI, reduction in severity of disease is noted [4] with
hyperinsulinism being resolving or transient in nature.
The cause for transience, even in genetic forms of HI, is
not known but is well recognised, particularly in those
without identified gene mutations [5].
There are few descriptions of the natural history of HI
and most long-term follow up studies have focused on
neurodevelopmental outcomes and time to resolution in
cross sectional observations only in patients with genet-
ically confirmed HI, ignoring transient forms. The inci-
dence of adverse neurodevelopmental outcomes in
patients with HI has been significant - varying between
26 and 44% in large patient groups, and has remained
static over the last two decades despite advances in diag-
nosis and management [4, 6–8]. Poor neurological out-
comes have also been found in transient HI patients and
do not differ in incidence when compared to patients
with persistent HI [9, 10]. Long-term conservative man-
agement of HI has been shown to be associated with the
remission of clinical symptoms by several groups [5, 8,
11] with the mean time to resolution on diazoxide treat-
ment reported to be 4.8 years [12]. In this subgroup of
patients, learning difficulties have been reported in 29%
following resolution of symptoms [8].
While considerable data exist to describe relatively
large birth weight in neonates with HI [13], there is little
natural history data regarding growth after diagnosis.
Mazor-Aronovitch et al. described a longitudinal cohort
of 21 patients in whom height in follow up was deemed
appropriate for parental target heights in 20 patients but
did not provide longitudinal auxology data [8]. Similarly,
Su et al. describe a “normal growth rate” in a study of 27
patients with HI but without providing specific data
[14]. Two studies have described the low risk of growth
deceleration in patients receiving octreotide but the
focus of these studies was on the medication’s potential
for growth suppression rather than the natural history of
the disease [12, 15]. Cherian et al. compared weight of
post pancreatectomy HI patients with age matched Type
1 diabetes patients and found no significant difference
[16]. To our knowledge there is no description in the lit-
erature of the long-term height and weight of HI pa-
tients from a large cohort.
Therefore, the aims of this study were to review
auxology of patients with HI and to review outcomes of
medication/disease resolution, feeding and neurodeve-
lopmental status in follow up assessment to describe the
longitudinal variation of illness due to HI.
Methods
All patients treated for HI in our centre over a three-
year period between 2011 and 2013 were entered into
the NORCHI (Northern Congenital Hyperinsulinism
Service) database and followed up over a period of five
years. The NORCHI service is a quaternary service for
the clinical management of patients with HI in the north
of the UK. Patients are referred to NORCHI from re-
gional neonatal units, district general hospitals and other
tertiary endocrine centres in the UK.
Patients were included in the study if they had
hypoglycaemia secondary to HI, required medical or sur-
gical treatment for HI and had undergone a period of
follow up in our centre. The diagnosis of HI was based
on the finding of detectable insulin at the time of
hypoglycaemia analysed from venous blood samples in
association with supraphysiological glucose infusion
rates and recurrent episodes of hypoglycaemia without
alternative causes, as per criteria described elsewhere
[17, 18]. Patients with HI secondary to being born small
for gestational age (SGA) were included if HI persisted
beyond 2 weeks of life. Patients with HI born to mothers
with diabetes/gestational diabetes and those with peri-
natal stress were excluded. Regardless of birth weight,
patients were also excluded if HI resolved within 4
weeks. Gene mutation analysis was performed as per a
testing algorithm described elsewhere [19]. Genetic ana-
lysis included Sanger sequencing for ABCC8 and
KCNJ11 as well as targeted gene panel using next gener-
ation sequencing. Genetic test results did not form part
of inclusion or exclusion criteria as it was felt to be im-
portant to capture data from a full cohort of patients
with HI.
Data regarding auxology, genetic investigations, neuro-
developmental status and feeding outcomes were ob-
tained by reviewing the database and electronic patient
records. Five year follow up data was obtained as close
to the fifth birthday as possible. Patients (n = 2) who pre-
sented outside the neonatal period also had data mea-
sured at birthday milestones rather than time since
diagnosis.
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Following discharge from the hospital, patients were
reviewed in the outpatient department where they were
always weighed and measured using the same measuring
board/stadiometer and weight scales by a variety of
trained observers. Additional information was retro-
spectively obtained from patient records. Longitudinal
outcomes included height, weight, medication dosages
and method of feeding at 3-, 6-, 12-, 24-, 36-, 48- and
60months. Neurodevelopmental outcomes were
reviewed at 60 months only. Neurodevelopmental prob-
lems were classed as none, some or severe as described
previously [9] through a combination of formal psycho-
metric testing and neurodevelopmental assessment by a
developmental paediatrician. Some neurodevelopmental
delay was defined as mild cognitive delay or learning dif-
ficulties. Severe neurodevelopmental problems were
classed as seizures, autism, cortical blindness, cerebral
palsy or severe developmental delay. Feeding problems
were classified as requirement for nasogastric (NG) or
gastrostomy tube to deliver at least a proportion of feeds
every day. Auxology data were converted to standard de-
viation scores (SDS) using population specific data for
UK children [20]. Disease was classed as persistent if the
patient had ever undergone surgery or was requiring
medication to treat hypoglycaemia at that time point.
Transient disease was classed as spontaneous resolution
of disease. In the absence of a uniform and/or consensus
definition of transient HI and the recognition that reso-
lution of HI can be both early and late [4, 5], transience
of HI was not time limited but assessed within the longi-
tudinal model of the study. Resolution was defined as
having undergone an age appropriate fast off medication
with no hypoglycaemia.
The study design was observational with no a priori
hypothesis in the absence of previous comparable data
and/or longitudinal observations in HI cohorts. Power
calculations were not performed for these reasons.
Statistical analysis
Patients who had ≥5 missing weight values or ≥ 4 miss-
ing height values (more than half of available observa-
tions) were excluded from analysis for that outcome. For
patients with < 5 or < 4 missing values for weight and
height respectively, imputation was used to complete
data sets. Seven separate simulations were run having
systematically excluded 1, 2, 3 values for height and 1, 2,
3, 4 values for weight and then five different imputation
methods were used to predict the missing values:
Splines, Mean, Median, Linear and Last Observation
Carried Forward. Complete cases were then used to val-
idate the imputed value against the true value. Accuracy
of imputation was measured using mean square error,
mean absolute error, root mean square error and mean
absolute percentage error. After 100 iterations had been
run, linear interpolation was found to be the most accur-
ate. This was then used to calculate missing variables for
weight and height data for those patients included in
analysis (Fig. 1).
Remaining data were analysed by IBM SPSS 25.
Mann-Whitney U tests were used to assess for differ-
ences in average insulin levels and early maximum diaz-
oxide dose between subgroups. Chi-square and Fisher’s
Exact tests were used to assess for differences in per-
centages of patients with permanence of HI between
subgroups such as high or low maximum early diazoxide
dose.
The study was conducted as per local research ethical
approval (reference 07/H1010/88).
Results
Genetic profiling
Seventy patients were enrolled into the cohort study
(Fig. 2). Only two patients were diagnosed outside the
neonatal period and were aged 8 months and 14months
at diagnosis. HI was diagnosed with mean (interquartile
range (IQR)) insulin level 73 (67) pmol/L at
hypoglycaemia with a mean (IQR) plasma glucose of 1.6
(1.2) mmol/L. In fourteen (20%) patients a disease-
causing variant was identified by Sanger sequencing or
targeted next generation sequencing; genetic testing was
not performed if patients demonstrated a resolving
course of disease. Eleven patients had disease-causing
variants in the ABCC8 or KCNJ11 gene, which encode
the pancreatic K-ATP channel, while the rest had muta-
tions in HNF4A (two patients) and GCK (one patient).
Six patients required a lesionectomy for the treatment of
focal HI and two required subtotal pancreatectomy for
non-focal HI.
Auxology profiles
Full set weight data (measured value available for every
time point) was obtained for 32 patients while linear
interpolation was used to impute missing values for
another 28 (Fig. 3a). Ten patients were excluded from
longitudinal analysis due to insufficient available mea-
surements (missing more than half their possible mea-
surements). Mean (IQR) weight SDS at birth was − 1.00
(3.65) with reduction at age 3 months to − 1.27 (2.89)
followed by recovery to − 0.06 (1.87) by age 4 years when
it remained stable until age 5 years (Fig. 3a). Of the co-
hort, only four patients (7%) had weight SDS > + 2.0 at 5
years. Mean weight SDS at birth was − 3.2 for SGA
patients and + 0.4 for non-SGA patients. For non-SGA
patients, birthweight SDS was similar in those with and
without genetic mutations (p = 0.098 for difference be-
tween the two).
Full set height data was obtained for 30 patients while
linear interpolation was used to impute missing values
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Fig. 2 Flowchart of natural history outcomes of HI. Frequency of patients in each category determined by time of presentation, mutation status,
transient/persistent and surgical outcomes
Fig. 1 Graphical representation of median and interquartile range for weight and height values from raw and imputed data. The graphs above
demonstrate the reliability of linear interpolation used for data imputation in this study. As can be seen, there are no changes in the trends for
weight (a) and height (b) when imputed data (i) were used compared with raw data (ii) alone
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for another 22 (Fig. 3b). Eighteen patients were excluded
in longitudinal analysis due to insufficient available mea-
surements (missing more than half their possible mea-
surements). Mean (IQR) height SDS at 3 months was −
1.5 (3.5) which increased to − 0.06 (1.8) at 12 months
and remained stable until 5 years with a height SDS of +
0.05 (1.2) (Fig. 3b). Figure 3a and b show cross sectional
summary measurements at each follow up to demon-
strate auxology increments in review appointments.
Only five patients received octreotide after discharge
from hospital and all achieved a normal height by the
age of 5 years (range − 0.3 to + 1.3 SDS for height). There
was no significant difference between height SDS during
and after treatment with octreotide.
There were 12 children (17%) with feeding problems
at 3 months and a steady reduction was observed over
time with only two children (3%) having problems with
feeding by 4 years of age, a figure which persisted until
Fig. 3 a Box and whisker plot analysis of median weight SDS by age. This demonstrates a lower than average birth weight with a trend towards
the population median weight at 24 months. Each box extends from the lower quartile to the upper quartile of the data used with the horizontal
line in the box indicating the sample median. The whiskers extend to the smallest and largest observations within 1.5*IQR from the lower and
upper quartiles, respectively. Any data points plotted beyond the ends of either whisker (as circles) are regarded as possible outliers. b. Box and
whisker plot analysis of median height SDS by age. This demonstrates an initially lower than average height, in keeping with weight, with a trend
back to population median height. Each box extends from the lower quartile to the upper quartile of the data used with the horizontal line in
the box indicating the sample median. The whiskers extend to the smallest and largest observations within 1.5*IQR from the lower and upper
quartiles, respectively. Any data points plotted beyond the ends of either whisker (as circles) are regarded as possible outliers
Worth et al. Orphanet Journal of Rare Diseases          (2020) 15:162 Page 5 of 9
5 years (Fig. 4). The two patients with persistence to 5
years both had diffuse HI. One of these patients had a
dominantly-acting de novo ABCC8 mutation.
Neurodevelopmental outcomes
At age 5 years, neurodevelopmental delay was docu-
mented in 11 patients (15%); these were either mild cog-
nitive delay or learning difficulties at school (defined as
some neurodevelopmental delay) in ten patients. How-
ever, one patient was found to have severe neurodeve-
lopmental delay and also developed autism during the
follow up period. One of the patients with neurodeve-
lopmental delay had a paternally inherited ABCC8 muta-
tion and focal CHI, all others had no identified mutation
and non-focal CHI. There was no statistically significant
association between neurodevelopmental outcomes and
either the presence of a genetic mutation or focal CHI.
Diazoxide as a severity and prognostic marker
All patients were started on diazoxide as a first line
treatment for HI. The mean (IQR) initial maximum
diazoxide dose (mg/kg/day) was significantly higher in
focal versus non-focal HI (11.8(6.3) vs 6.4(2.4), p = 0.003)
as well as in those with a KATP mutation versus those
without (11.1(8.8) vs 5.9(1.5), p < 0.001) and in those
who required surgery versus those who did not
(11.3(8.8) vs 6.3(8.8), p = 0.001). Mean (IQR) initial max-
imum dose (mg/kg/day) was also higher in those with
persistent versus transient HI at 6 months (8.0(5.8) vs
5.6(0.7), p = 0.007) and at 5 years (9.4(10.0) vs 6.4(2.5),
p = 0.015), indicating the high value of diazoxide dosage
as a severity and prognostic marker in the early stages of
diagnosis. A cut off maximum diazoxide dose of 5 mg/
kg/day was found to be a predictor of spontaneous reso-
lution at 6 months and at 5 years [Table 1]. Patients re-
ceiving > 5 mg/kg/day of diazoxide soon after diagnosis
to stabilise hypoglycaemia had a higher probability of
persistent disease at 6 months (62% vs 32%, chi square =
5.895, p = 0.015) and at 5 years (27% vs 7%, chi square
5.395, p = 0.02) than those receiving ≤5 mg/kg/day.
Resolution of HI
Spontaneous resolution was observed in 19 patients
(27%) at 3 months of age. This number steadily rose to
60 patients (86%) with spontaneous resolution at 5 years
of age (Fig. 5). A further eight patients underwent sur-
gery and of these, seven were able to stop all medication
by age 5 years. This left only three patients (4%) requir-
ing medication for hypoglycaemia aged 5 years, one of
whom had undergone a subtotal pancreatectomy.
Babies with HI who were born small for gestational
age (SGA) had a lower chance of persistence of disease
at 6 months than those not born SGA (29% vs 38%, p =
0.009). This continued to 5 years of age where SGA chil-
dren had a much lower chance of persistence of disease
than those not born SGA (0% vs 23%, p = 0.012).
Discussion
We have described auxology, medication, feeding and
neurodevelopmental outcomes in a 5 year longitudinal
cohort of patients with HI in a single centre. While neu-
rodevelopmental outcomes and time to resolution have
been reported in many studies, there are no reports of
Fig. 4 Percentage of children with feeding difficulties by age. Demonstration that the percentage of children with HI and feeding difficulties
reduced from a maximum of 17% at 3 months of age to only 3% at 48 months of age. Feeding difficulties were classified as requirement for
nasogastric or gastrostomy feeding
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the natural history of HI with regards to height, weight,
feeding or medication.
The median birth weight of this cohort was below
average, contrary to typical descriptions of patients with
HI being large at birth. The reasons for lower than ex-
pected birth weight is not clear but could be due to the
increased frequency of HI secondary to SGA birth
weight babies. However, in subset analysis, patients not
born SGA were also not large at birth, with a mean
weight SDS of + 0.4. In the context of a relatively low
birth weight and liberal use of carbohydrates to prevent
and treat hypoglycaemia, we did not demonstrate early
life excess weight gain tracking through to later child-
hood. Height was very well preserved in our patients in-
dicating that nutritional management of hypoglycaemia
does not adversely impact upon growth. An initially low
SDS for height at three months recovered quickly and
patients achieved a normal height at 5 years. Although
we have demonstrated satisfactory auxology in a 5 year
follow up, the longer-term outcomes remain unknown.
Longer follow up studies in diverse populations will be
required to address risk in adult life.
Feeding problems are frequent in many patients with
HI in early life [21] and these may persist for many years
[22]. The requirement for supra-physiological calorie in-
take (via artificial enteral and intravenous dextrose ad-
ministration [23]), diazoxide induced-nausea and
reduced opportunities for breast or bottle feeds creates
an environment primed for infant feeding problems [24].
Despite input by our Multidisciplinary Team (MDT)
comprising dietetic and speech and language therapy,
17% of patients with HI required some form of artificial
feeding at 3 months. This frequency reduced over time
with continued MDT input; by 4 years of age 97% were
feeding orally without supplementation. This data is im-
portant in determining the risk of long-term harm from
early life treatment as, at an age of developmental plasti-
city, modification of energy and carbohydrate intake
may have profound implications for the risk of obesity
and cardiovascular disease in later life [25].
The prevention of neurodevelopmental problems sec-
ondary to hyperinsulinaemic hypoglycaemia is a corner-
stone of HI management. In spite of treatment advances,
there has been only a minimal reduction in the rate of
this complication over the last two decades5,6. In our co-
hort, we demonstrated a lower rate of neurodevelop-
mental problems (15%), most of which were mild, than
in other studies7. The cause for a reduction in
Fig. 5 Percentage of children with persistent disease. Children either requiring medication or who had undergone surgery were classed as
having persistent disease. This demonstrates the steady improvement in spontaneous resolution of patients with HI
Table 1 Resolution of HI in relation to maximal diazoxide dose
Resolution of HI Diazoxide < 5mg/kg/day
(n = 44)
Diazoxide > 5mg/kg/day (n = 26) p-value for difference
Resolution at 6 months
n (%)
30 (68%) 10 (38%) 0.015
Resolution at 5 years
n (%)
41 (93%) 19 (73%) 0.020
A diazoxide dose < 5mg/kg/day was associated with a greater tendency to resolution both at 6 months and at 5 years. Significant differences are shown as p
values for Chi-squared tests
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neurodevelopmental problems has not been explored in
this study but could be a consequence of the impact of
early detection and prompt treatment of hypoglycaemia
promoted at our centre. It is possible that our relatively
high rate of transient HI may account for this reduction.
However, previous studies have shown no difference in
neurodevelopmental outcomes between those with tran-
sient and permanent HI [9].
In the absence of a marker of disease severity, predicting
long-term outcomes for the many subgroups of patients
with HI is challenging. In this study, we found that the
maximal diazoxide dose around the time of diagnosis had a
real prognostic value. A higher dose correlated with a
greater likelihood of disease persistence, indicating that
dose may be used as a proxy marker along with SGA status
to determine long-term outcome. In a disease for which it
is notoriously difficult to predict outcomes this information
will help in counselling families and planning treatment. As
there is no standard marker of a “good response” to diazox-
ide, having a cut off value is also helpful for future predic-
tion and can be easily explained to parents.
Another factor with predictive value on long term
resolution or persistence was whether the patient had
been born SGA. Recent studies have suggested the pres-
ence of SGA as a predictor of earlier resolution [26] and
our data are entirely consistent with this. However, not
all patients born SGA underwent resolution of HI within
a few weeks; 29% of SGA patients continued to have HI
beyond 6months. The cause for this observation has not
been explored in our study but SGA status used with
early maximum diazoxide dose could help plan treat-
ment options and give families some realistic projections
of expected outcomes.
We recognise that a potential limitation of our study is
the relatively high numbers of patients with transient HI
and without confirmed genetic mutations. However, our
study reflects the real-world nature of cohorts of patients
with HI unaffected by referral bias skewed towards the
most severe and persistent of patients. Further, inclusion
of patients with SGA and Transient HI has several ad-
vantages. Inclusion enables an unselected and unbiased
review of frequency of disease persistence in longitudinal
follow up and provides valuable insight into the effect of
supraphysiological nutritional supplementation and
growth restricting therapies at a critical plastic period in
human development. We acknowledge that our study
criteria exclude babies born SGA in whom HI resolved
within 2 weeks; therefore, our study inferences regarding
auxology, medication, resolution and feeding are not
generalisable to all SGA babies.
Conclusions
We have detailed the first description of a five-year lon-
gitudinal cohort of HI patients to show maintenance of
auxological parameters without risk of early life obesity
secondary to excess carbohydrate usage in early life.
Height is well preserved amongst this group implying
provision of adequate nutrition for growth. Feeding
problems occurred in a significant proportion but the
frequency reduced with sustained multidisciplinary in-
terventions. The incidence of patients with neurodeve-
lopmental delay at 5 years was lower than previously
reported, implying an optimistic shift from previous high
rates over the past decade.
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